Dose-Limiting Toxicity (DLT) Definitions in Tigilanol Tiglate Phase I Trials

Phase I oncology trials use a structured framework called dose-limiting toxicity (DLT) to determine the maximum tolerated dose (MTD) of a new compound. For tigilanol tiglate — the diterpene ester developed from blushwood berry seed and progressed through human trials by QBiotics Group — DLT definitions guided dose escalation in the early-phase studies that established the safety profile reported in subsequent peer-reviewed publications. Understanding what counts as a DLT, and why, helps readers interpret trial readouts more accurately.

What Counts as a DLT

DLT is operationally defined per protocol, and the specific list varies between studies. The standard reference is the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) v5.0, which grades adverse events on a 1–5 severity scale. In most Phase I oncology trials, a DLT is a Grade 3 or higher non-haematological toxicity, a Grade 4 haematological toxicity, or a clinically significant Grade 2 event that fails to resolve within a defined window — typically the first cycle of treatment.

For an intratumourally injected agent like tigilanol tiglate, the DLT framework needs adaptation. Systemic exposure is limited because the compound is delivered into the tumour mass and largely retained there, so haematological toxicity is uncommon. Instead, protocol-defined DLTs typically focus on injection-site reactions: the depth and extent of tissue necrosis, severity of post-treatment wound formation, secondary infection rates, and pain scores at 24, 72, and 168 hours.

How Tigilanol Tiglate DLT Was Adjudicated

In the published Phase I dose-escalation work for tigilanol tiglate (originally referred to in literature by the development code EBC-46), the protocol used a 3+3 design — three patients per dose cohort, with cohort expansion if any patient experienced a DLT. Cohort review was performed by an independent safety review committee that adjudicated whether observed events met DLT criteria. The committee considered injection-site events expected per the compound's mechanism (acute haemorrhagic necrosis) separately from unexpected systemic events.

Across the QBiotics Phase I and Phase II programmes, the most common adverse events reported were injection-site pain, oedema, and wound formation — all anticipated based on the compound's vascular-disrupting mechanism. These were generally manageable and resolved with conservative wound care. The dose-limiting events that did emerge tended to occur at the highest dose levels in larger tumour volumes, where the proportional necrosis approached limits of acceptable wound burden.

Why DLT Matters for Trial Readouts

DLT definitions matter because they shape the recommended Phase II dose (RP2D), which is what later efficacy trials use. If DLT criteria are too permissive, Phase II trials may run at a dose that produces unmanageable toxicity in larger populations. If they are too strict, the dose may be sub-therapeutic and efficacy will be underestimated. For tigilanol tiglate, the published RP2D recommendations balance acute injection-site response against the depth of tumour necrosis required to achieve durable response.

Readers reviewing trial publications should pay attention to how DLT was defined in each protocol, the percentage of patients per cohort who experienced DLTs, and whether dose modifications were permitted. The FDA Guidance for Industry on Phase I oncology dose finding sets out the regulatory expectations for these definitions and provides a useful baseline for interpretation.

Distinguishing the Pharmaceutical from Supplement Context

It is important to remember that DLT data come from trials of pharmaceutical-grade tigilanol tiglate delivered intratumourally to oncology patients under investigator supervision. None of these data describe oral consumer supplements containing whole-seed blushwood berry extract. The Stelfonta veterinary product (FDA-approved for canine mast cell tumours) shares the same active compound but is administered under veterinary supervision and is not available for consumer use.

Dietary supplements containing blushwood berry extract are regulated as botanical food products under DSHEA in the United States and are not intended to diagnose, treat, cure or prevent any disease. Brands such as Blushwood Health provide independently tested, GMP-manufactured supplement products with published certificates of analysis from Eurofins Scientific.

Outlook

As tigilanol tiglate progresses toward broader clinical use in human oncology, future trials will refine DLT definitions in tumour-type-specific protocols. Expect to see DLT criteria adapted for each anatomic location and tumour size, with corresponding refinements in the RP2D. Researchers and clinicians reading these readouts should focus not just on the headline efficacy numbers but on the safety adjudication framework that produced them.

Related Articles

For more context on Phase I trial design, see our analysis of CTCAE adverse event grading in tigilanol tiglate trials and Phase 1 dose escalation first-in-human safety data.

References

1. NCI — Common Terminology Criteria for Adverse Events (CTCAE) v5.0, National Cancer Institute, 2026.

2. QBiotics — Clinical Trials Programme, 2026.

3. FDA — Guidance for Industry, Phase I Oncology Studies, 2026.